This suggests that Erk may also regulate the PARP-1-dependent activation of NFκB [40], further points to a role for this interaction in cancer, as dysregulated Erk pathways are thought to be a present in an estimated one-third of cancers [59]. This evidence concerns the gene NFKB1 and cancer.